Related Experiment Video
Updated: Jun 27, 2026
07:49
Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Polymorphisms in mitochondrial genes and prostate cancer risk
Liang Wang1, Shannon K McDonnell, Scott J Hebbring
1Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, MN 55905, USA.
Summary
Mitochondria and prostate cancer risk were investigated using genetic variations. No significant associations were found for mitochondrial or nuclear-encoded mitochondrial genes, suggesting they are not major risk factors.
Area of Science:
- Genetics
- Oncology
- Mitochondrial Biology
Background:
- Mitochondria, traditionally viewed as energy producers, have diverse roles and are linked to diseases like cancer.
- Prostate cancer risk is influenced by genetic factors, prompting investigation into mitochondria-related genes.
Purpose of the Study:
- To determine if genetic variations in mitochondrial and nuclear-encoded mitochondrial genes increase prostate cancer risk.
- To analyze single-nucleotide polymorphisms (SNPs) and haplotypes within mitochondrial and nuclear-encoded mitochondrial genes.
Main Methods:
- Genotyped 24 mitochondrial genome SNPs and 376 tagSNPs in 78 nuclear-encoded mitochondrial genes.
- Compared allele and haplotype frequencies in ~1,000 prostate cancer cases and ~500 controls.
- Evaluated associations, including comparisons with existing Cancer Genetic Markers of Susceptibility (CGEMS) data.
Main Results:
- No significant association was detected for mitochondrial genome SNPs or common mitochondrial haplotypes with prostate cancer.
- None of the tagSNPs in nuclear-encoded mitochondrial genes showed significant association after adjusting for multiple testing.
- Seven tagSNPs showed unadjusted significance in this study and CGEMS phase I, but were not replicated in CGEMS phase II.
Conclusions:
- Polymorphisms in the evaluated mitochondrial genome and nuclear-encoded mitochondrial genes do not appear to be substantial risk factors for prostate cancer.
- Further research may be needed to explore other genetic or environmental factors contributing to prostate cancer susceptibility.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:59Animal Mitochondrial Genetics
Among all the organelles in an animal cell, only mitochondria have their own independent genomes. Animal mitochondrial DNA is a double-stranded, closed-circular molecule with around 20,000 base pairs. Mitochondrial DNA is unique in that one of its two strands, the heavy, or H, -strand is guanine rich, whereas the complementary strand is cytosine rich and called the light, or L, -strand. Compared to nuclear DNA, mitochondrial DNA has a very low percentage of non-coding regions and is marked by...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...